T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection by Martínez-Bravo, MJ et al.
Published by Baishideng Publishing Group Inc
ISSN 1948-5182 (online)
World Journal of 
Hepatology
World J Hepatol  2017 September 28; 9(27): 1115-1132
Contents Three issues per month  Volume 9  Number 27  September 28, 2017








Nicolas C, Le Gouge A, d’Alteroche L, Ayoub J, Georgescu M, Vidal V, Castaing D, Cercueil JP, Chevallier P, Roumy J, 
Trillaud H, Boyer L, Le Pennec V, Perret C, Giraudeau B, Perarnau JM; STIC-TIPS group
Contents
World Journal of Hepatology




Responsible Assistant Editor: Xiang Li             Responsible Science Editor: Fang-Fang Ji
Responsible Electronic Editor: Dan Li             Proofing Editorial Office Director: Jin-Lei Wang
Proofing Editor-in-Chief: Lian-Sheng Ma
NAME	OF	JOURNAL	






36 Issues/Year (8th, 18th, and 28th of  each month) 
EDITORS-IN-CHIEF
Clara Balsano, PhD, Professor, Departement of 
Biomedicine, Institute of  Molecular Biology and 
Pathology, Rome 00161, Italy
Wan-Long Chuang, MD, PhD, Doctor, Professor, 
Hepatobiliary Division, Department of  Internal 
Medicine, Kaohsiung Medical University Hospital, 
Kaohsiung Medical University, Kaohsiung 807, Taiwan
EDITORIAL	BOARD	MEMBERS




World Journal of  Hepatology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 







Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 









© 2017 Baishideng Publishing Group Inc. Articles pub-
lished by this Open Access journal are distributed under 
the terms of  the Creative Commons Attribution Non-
commercial License, which permits use, distribution, 
and reproduction in any medium, provided the original 
work is properly cited, the use is non commercial and is 
otherwise in compliance with the license.
SPECIAL	STATEMENT
All articles published in journals owned by the 
Baishideng Publishing Group (BPG) represent the 
views and opinions of  their authors, and not the views, 














World Journal of  Hepatology (World J Hepatol, WJH, online ISSN 1948-5182, DOI: 
10.4254), is a peer-reviewed open access academic journal that aims to guide clinical 
practice and improve diagnostic and therapeutic skills of  clinicians.
WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, 
liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory 
disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary 
tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, 
epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric 
hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. 
Priority publication will be given to articles concerning diagnosis and treatment of  
hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory 
diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological 
diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical 
diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional 
treatment, minimally invasive therapy, and robot-assisted therapy. 
We encourage authors to submit their manuscripts to WJH. We will give priority 
to manuscripts that are supported by major national and international foundations and 
those that are of  great basic and clinical significance.
World Journal of  Hepatology is now indexed in Emerging Sources Citation Index (Web of  
Science), PubMed, PubMed Central, and Scopus.
I-IV  Editorial	Board
María José Martínez-Bravo, Berta Sánchez, José Manuel Sousa, María José Acevedo, Miguel Angel Gómez-
Bravo, Antonio Núñez-Roldán, Isabel Aguilera
ORIGINAL ARTICLE
1115 September 28, 2017|Volume 9|Issue 27|WJH|www.wjgnet.com
T-cell allorecognition of donor glutathione S-transferase T1 
in plasma cell-rich rejection
Retrospective Study
María José Martínez-Bravo, Berta Sánchez, María José 
Acevedo, Antonio Núñez-Roldán, Isabel Aguilera, Immunology 
Service, Instituto de Biomedicina de Sevilla, Hospital Universitario 
Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, 
Spain
José Manuel Sousa, Digestive Diseases Service, Hospital 
Universitario Virgen del Rocío, 41013 Seville, Spain
Miguel Angel Gómez-Bravo, Liver Transplant Unit, Hospital 
Universitario Virgen del Rocío, 41013 Seville, Spain
Author contributions: Martínez-Bravo MJ designed and 
performed the research and contributed to the analysis; Acevedo 
MJ performed the experiments and acquired the data; Sousa 
JM and Gómez-Bravo MA provided samples and the clinical 
information of the patients; Sánchez B contributed to the analysis 
and revised the manuscript; Núñez-Roldán A critically reviewed 
the manuscript; Aguilera I designed the study, analyzed the data 
and wrote the manuscript.
Supported by The Spanish Ministry of Economy, Instituto de 
Salud Carlos III, Nos. 10/2332 and 11/857; and the Andalusian 
government, No. PI-0332-2007, for which Martinez-Bravo MJ 
was a pre-doctoral fellow. Aguilera I is a senior researcher from 
the Nicolás Monardes program.
Institutional review board statement: This study was reviewed 
and approved by the Ethics Committee of the University Hospital 
Virgen del Rocío, Seville, Spain.
Informed consent statement: Patients were not required to 
give informed consent to this study because they have been enrolled 
in previous projects and this was a continuation of the research 
for which they gave a general consent.
Conflict-of-interest statement: The authors have no financial 
relationships to disclose.
Data sharing statement: No additional data are available. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Isabel Aguilera, PhD, Immunology 
Service, Instituto de Biomedicina de Sevilla, Hospital Universitario 
Virgen del Rocío/CSIC/Universidad de Sevilla, Avda. Manuel 
Siurot s/n, 41013 Seville, Spain. iaguilera-ibis@us.es 
Telephone: +34-95-5923120
Received: January 26, 2017    
Peer-review started: February 8, 2017
First decision: March 27, 2017
Revised: April 6, 2017
Accepted: June 12, 2017
Article in press: June 13, 2017
Published online: September 28, 2017
Abstract
AIM
To investigate the role of glutathione S-transferase 
T1 donor-specific T lymphocytes in plasma cell-rich 
rejection of liver allografts.
METHODS
The study group included 22 liver transplant patients. 
Among them, 18 patients were mismatched for the 
glutathione S-transferase T1 (GSTT1) alleles (don+/
rec-), and 4 were matched (don+/rec+). Seven of the 
mismatched patients produced anti-GSTT1 antibodies 
and developed plasma cell-rich rejection (former de 
novo  immune hepatitis). For the detection of specific T 
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lymphocytes, peripheral blood mononuclear cells were 
collected and stored in liquid nitrogen. The memory T 
cell response was studied by adding to the cell cultures 
to a mix of 39 custom-made, 15-mer overlapping 
peptides, which covered the entire GSTT1 amino acid 
sequence. The specific cellular response to peptides 
was analyzed by flow cytometry using the markers 
CD8, CD4, IL-4 and IFNγ.
RESULTS
Activation of CD8+ T cells with different peptides was 
observed exclusively in the group of patients with 
plasma-cell rich rejection (3 out of 7), with production 
of IL-4 and/or IFNγ at a rate of 1%-4.92% depending 
on the peptides. The CD4+ response was most common 
and not exclusive for patients with the disease, where 
5 out of 7 showed percentages of activated cells from 
1.24% to 31.34%. Additionally, two patients without 
the disease but with the mismatch had cells that 
became stimulated with some peptides (1.45%-5.18%). 
Highly unexpected was the finding of a double positive 
CD4+CD8low T cell population that showed the highest 
degree of activation with some of the peptides in 7 
patients with the mismatch, in 4 patients with plasma 
cell-rich rejection and in 3 patients without the disease. 
Unfortunately, CD4+CD8low cells represent 1% of the 
total number of lymphocytes, and stimulation could 
not be analyzed in 9 patients due to the low number 
of gated cells. Cells from the 4 patients included 
as controls did not show activation with any of the 
peptides. 
CONCLUSION
Patients with GSTT1 mismatch can develop a specific 
T-cell response, but the potential role of this response 
in the pathogenesis of plasma cell-rich rejection is 
unknown. 
Key words: Donor-specific glutathione S-transferase 
T1 antibodies; Indirect presentation; Glutathione 
S-transferase T1-memory T cells; De novo  immune 
hepatitis; Donor/recipient mismatch
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In solid organ transplants, donor recipient 
mismatch of glutathione S-transferase T1 (GSTT1) 
alleles triggers a specific immune response with 
the production of IgG antibodies. In a proportion of 
mismatched liver and kidney transplants, the clinical 
outcome is rejection. However, detection of GSTT1-
specific T lymphocytes has not been documented. We 
provide the first evidence of T cells able to become 
activated by GSTT1 peptides in patients who develop 
plasma cell-rich (PC-rich) rejection after GSTT1-mismatch 
liver transplantation. Interestingly, not only CD8+ or 
CD4+ cells but also double positive CD4+CD8low cells 
reacted to the antigenic stimulation in vitro . 
Martínez-Bravo JM, Sánchez B, Sousa JM, Acevedo MJ, Gómez-
Bravo MA, Núñez-Roldán A, Aguilera I. T-cell allorecognition of 
donor glutathione S-transferase T1 in plasma cell-rich rejection. 
World J Hepatol 2017; 9(27): 1115-1124  Available from: URL: 
http://www.wjgnet.com/1948-5182/full/v9/i27/1115.htm  DOI: 
http://dx.doi.org/10.4254/wjh.v9.i27.1115
INTRODUCTION
In the context of liver transplantation, both glutathione 
S-transferase T1 (GSTT1) mismatch and the pre-
sence of GSTT1 antibodies have been associated with 
the development of de novo immune hepatitis[1-3], 
recently accepted as a rejection of the liver allograft 
in which allogeneic hepatocytes that express GSTT1 
constitutively in their cytoplasm are the main targets 
of the immune response. The Banff Working Group 
on Liver Allograft Pathology has recently updated the 
terminologies of post-transplant complications and 
encourages the use of “plasma cell-rich rejection” 
instead of the former “de novo autoimmune hepatitis”[4]. 
Therefore, in this manuscript, we will use the new 
terminology.
Plasma cell-rich (PC-rich) rejection is a liver disorder 
of unclear pathogenesis that is usually diagnosed 
within the first two years after liver transplantation. A 
common feature of all the patients diagnosed in our 
hospital is the presence of GSTT1 antibodies due to the 
recognition of GSTT1 as a foreign antigen expressed in 
the graft when the recipient lacks this gene. Although 
it is a very specific anti-donor response, it is unclear 
whether these antibodies have a pathogenic effect 
since some patients with sustained antibody-titers will 
never develop PC-rich rejection. 
Pregnancy, transfusion and transplantation are 
circumstances where the host immune system is able 
to recognize foreign major and minor histocompatibility 
antigens. This is the case for GSTT1, a drug meta-
bolizing enzyme that is abundantly expressed in 
the liver and kidney. Recipients who lack this gene 
(GSTT1*0/0) might generate antibodies against GSTT1 
after blood transfusion and/or organ transplantation 
from GSTT1-positive donors (GSTT1*A/0 or *A/A)[5,6]. 
It has been reported that the GSTT1 protein is able to 
induce a memory B cell response in GSTT1*0/0 women 
after pregnancy with GSTT1-positive offspring[6]. 
Moreover, it has been demonstrated that GSTT1-
specific plasma cells are quickly activated when a 
GSTT1-positive patient receives an infusion of hema-
topoietic cells from an HLA-identical sensitized donor[7]. 
The liver is a very special organ with a variety 
of important cell types able to function as APCs. 
Hepatocytes, which represent 60% of the liver cells, 
express MHC class Ⅰ at low levels and have the 
ability to serve as antigen presenting cells (APCs). 
Furthermore, under some pathological circumstances 
in a pro-inflammatory environment, parenchymal 
cells and biliary epithelial cells can express MHC 
class Ⅱ antigens[8]. Some studies in mouse models 
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have indicated that both CD4+ and CD8+ T cells can 
independently initiate hepatocyte rejection, more rapidly 
in the case of CD8+ cells, somehow preceding the CD4+ 
mediated response[9]. In humans, patients with chronic 
allograft failure of kidney grafts have significantly 
higher frequencies of CD4+ T cells indirectly activated 
by allogeneic peptides when compared with controls, 
whereas CD4+ T cells activated in a direct manner 
reduced the cytotoxic T cell response[10]. However, there 
are variables such as immunosuppression therapy that 
can alter the immunological response in different ways. 
In this study, we aim to explore the role of T cells 
in the context of PC-rich rejection. We have compared 
the T cell response in PBMCs collected from 18 GSTT1-
mismatched liver transplant patients, 7 of which had a 
diagnosis of PC-rich rejection, with 4 GSTT1-matched 
transplanted patients after re-stimulation in vitro with 
the whole set of GSTT1 peptides. In summary, we 
have the first evidence of GSTT1-specific memory T 
cells ready to become activated after recall with the 
antigen, but further studies will be needed to test the 
potential role of these cells in the pathogenesis of PC-
rich rejection.  
MATERIALS AND METHODS
Patients
The study group included 22 liver transplant patients, 
10 females and 12 males, who had transplants 
between June 1996 and April 2011. Eighteen of 
the patients lacked the GSTT1 gene and received a 
liver from a GSTT1 positive donor (rec-/don+). Con-
sequently, all of them were candidates to develop a 
specific immune response against this foreign antigen. 
Four additional patients without the GSTT1 mismatch 
(rec+/don+) were included as a control group. Within 
the mismatched patients, we observed three different 
types of immune and clinical responses regarding 
the GSTT1 antigen. Group 1 consisted of 7 patients 
who produced anti-GSTT1 antibodies and developed 
PC-rich rejection. Group 2 included 2 patients who 
produced anti-GSTT1 antibodies but did not develop 
PC-rich rejection. Group 3 included 9 patients who 
did not produce anti-GSTT1 antibodies (which always 
precede clinical manifestations) and consequently did 
not develop the disease. Written informed consent 
was obtained from all of the participants, and the 
procedures were in accordance with the Helsinki 
Declaration. The study protocol was approved by the 
Ethics Committee of the University Hospital Virgen 
del Rocío, Seville, Spain. Patient characteristics are 
described in Table 1. Baseline immunosuppression 
was cyclosporine in 13 cases and tacrolimus in 9 
cases, either alone or combined with mycophenolate 
mofetil and steroids during the first months. Cells 
were obtained at a mean time of 6.68 years after the 
transplant (1-16). Changes in the immunosuppression 
therapy at the time of cell extraction are described in 
Table 1. Six of the patients with PC-rich rejection were 
also receiving prednisone as a specific treatment, and 
one patient was not adequately diagnosed and died in 
2014. 
GSTT1 genotyping
Peripheral blood samples from the patients and their 
donors were collected, and genomic DNA was purified 
using the QIAmp DNA mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. 
Primers and conditions for the GSTT1 PCR reaction 
have been described in detail elsewhere[11]. 
Detection of GSTT1 antibodies 
Following the manufacturer’s protocol, total IgG anti-
bodies in sera were analyzed using a commercially 
available ELISA, which contains the human GSTT1 
recombinant protein (Biomedal, Seville, Spain). 
GSTT1 peptides
We selected 15-mer peptides that overlapped by 
9 amino acids and spanned the GSTT1 protein. In 
total, there were 39 peptides (Table 2). Peptides were 
synthesized by Innovative Peptide Solutions, JPT (Berlin, 
Germany). Peptide purity was higher than 80%, as 
assayed by HPLC, and the peptide composition was 
verified by mass spectrometry. Lyophilized peptides 
were dissolved at 10 mg/mL in DMSO, aliquoted, and 
stored at -20 ℃. 
Cell isolation and culture with the GSTT1 peptides
Post-transplant PBMCs were isolated using BD Vacu-
tainer CPT ficoll tubes (BD Biosciences, CA, United 
States), frozen in FCS containing 10% DMSO, and 
stored in liquid nitrogen. For stimulation experiments, 
3-4 × 105 cells were cultured in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal bovine 
serum (Biochrom AG, Berlin, Germany), Penicillin/
Streptomicin (100 U penicillin/mL, 100 µg streptomycin/mL), 
1 mmol/L Na-Piruvate (Sigma Aldrich, MI, EEUU) and 
L-Glutamine (2 mmol/L, Irvine Scientific, Wicklow, 
Ireland) in the presence of 8 pools, each one containing 
5 peptides and the last one containing only 4 (10 µg/mL 
each peptide). Next, 10 µg/mL anti-CD28/CD49d (BD 
Biosciences, CA, United States) was added for 48 h at 
37 ℃ 5% CO2, and 10 µg/mL Brefeldin A was added to 
the samples during the last four hours (Golgi Plug: BD 
Biosciences). A negative control (without peptide but 
with the proportional amount of DMSO) and a positive 
activation control with 10 ng/mL PMA + 1 µg/mL iono-
mycin (Sigma Aldrich) were included in each assay. 
Pre-transplant samples were not available.
In silico analysis of MHC-peptide binding affinity
HLA class Ⅰ and Ⅱ binding affinity to GSTT1 peptides 
was analyzed by the Immune Epitope Database (IEDB) 
and Analysis Resources NetMHCI/IIpan. 
Flow cytometry
Immunofluorescence staining was performed after 
Martínez-Bravo MJ et al . Immune response against liver GSTT1 antigen
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fixation and permeabilization using lysing solution 
(BD Biosciences, CA, United States) with the following 
surface and intracellular markers: Anti-human CD4-
PerCP/CD8-APC/IFNγ-FITC/IL-4-PE (Becton Dickinson 
BD Biosciences, CA, United States). Lymphocyte cyto-
kine release patterns were analyzed by flow cytometry 
(FACSort; BD Biosciences) using CELLQuest software. 
The specific cellular response to the different pools was 
calculated by subtracting the percentage of activation 
of T cells cultured without GSTT1 peptides (negative 
control). Typically, 50000 events were collected using 
FL3 (CD4PerCP-Cy5) or FL4 (CD8-APC) as a fluorescent 
trigger. A second set of gating was drawn to include 
CD8- or CD8low and IFNγ and IL-4 expression. 
RESULTS
Identification of memory T cell subsets specific for the 
GSTT1 antigen
We have categorized as positive the populations with 
more than 1% of activated cells. All of the patients 
who showed stimulation revealed a polyclonal T cell 
response since we observed stimulation with more 
than one peptide. For simplicity reasons, we have 
represented the highest percentage of cell activation 
among the positive values obtained with each peptide 
(Figure 1 and Table 3). The group of patients with PC-
rich rejection (group 1) was the only group in which 
activation of CD8+ T cells was detected in 3 patients, 
expressing IL-4, IFNγ or both cytokines simultaneously. 
This group also shows the most abundant and diverse 
patterns of CD4+ T cell activation exhibiting Th0 (IL-4/ 
IFNγ), Th1 (IFNγ) and Th2 (IL-4) pathways, although 
cellular activation is not exclusive of group 1 and was 
also observed in two patients included in group 3 
(Table 3). The most striking result was the presence of 
CD4+CD8low double positive (DP) cells that seem to be 
enriched in GSTT1-specific cells, especially cells with 
a secretion profile of both cytokines tested (3.44% 
patient 2, 78.95% patient 3, 9.54% patient 4, 4.56% 
patient 5). Unfortunately, DP cells are not abundant, 
and only 4 of the 7 patients with PC-rich rejection 
could be analyzed due to the low number of double 
positive cells gated in the remaining 3 cases. 
The patients with antibodies but without PC-rich 
rejection (group 2) did not show CD4+ or CD8+ T cell 
activation, whereas five of the 9 patients included in 
group 3, without antibodies and therefore without 
disease, exhibited stimulation with some peptides. 
Again, the higher percentages of activation occurred 
in the double positive CD4+CD8low cells (6.63% patient 
10, 29.58% patient 17 and 43.05% patient 18), 
although in some cases the number of double positive 
CD4+CD8low cells was too low to perform further 
analysis (Table 3). The four patients included as the 
control group with recipients and donors that were 
matched for the GSTT1 positive allele did not become 
activated with any of the peptides assayed.
In summary, 12 out of 18 liver transplant recipients 
with the GSTT1 mismatch showed different degrees of 
T lymphocyte activation upon exposure to the GSTT1 
peptides. Although we could not test for memory 
markers, the short time of stimulation (48 h) indicates 
that this is not a primary response but a reactivation 
of pre-existing GSTT1-specific lymphocytes. There 
are 3 cell types involved, including CD4+, CD8+ and 




Treatment at PBMC 
extraction
1 1 M 06-05-99 Alcoholic cirrhosis CYA (N), MMF, ST 12-04-12 13 CYA (N), MMF, ST
2 F 07-05-07 Cirrhosis probably autoimmune CYA, MMF, ST 16-04-12   5 CYA (N), MMF, ST
3 F 02-07-00 HCV cirrhosis CYA (N), ST, BASILISIMAB 13-03-12 12 TAC, AZA, ST
4 F 18-09-03 Alcoholic cirrhosis CYA, MMF, ST 09-05-12   9 TAC, MMF, ST
5 M 02-11-01 HCV + alcoholic cirrhosis CYA (N), ST, BASILISIMAB 14-06-12 11 MMF, ST
6 F 27-03-09 Primary biliary cirrhosis CYA, MMF 12-04-12   3 MMF, ST
7 F 18-11-06 Secondary biliary cirrhosis CYA (N), MMF, ST 08-05-12   6 CYA, MMF
2 8 M 23-11-96 HBV cirrhosis CYA (N), MMF, ST 19-06-12 16 CYA (N), MMF
9 F 03-06-96 Agenesis of the bile ducts CYA, ST 21-05-12 16 TAC
3 10 M 12-7-06 Alcoholic cirrhosis + hepatocarcinoma TAC, MMF, ST 16-04-12   6 MMF, SIR
11 M 12-02-09 HBV cirrhosis TAC, MMF, ST 16-04-12   3 MMF, SIR
12 M 06-07-10 Non-alcoholic steatohepatitis TAC (10 d) CYA, RAPA 17-04-12   2 MMF, SIR
13 M 19-04-11 HCV cirrhosis+ hepatocarcinoma CYA, ST 18-04-12   1 CYA, ST
14 M 18-01-09 HCV cirrhosis TAC, MMF, ST 02-05-12   3 TAC
15 F 18-06-04 Alcoholic cirrhosis TAC 07-05-12   8 MMF, EVE
16 M 30-07-08 HCV cirrhosis TAC, MMF, ST 08-05-12   4 MMF, EVE
17 M 20-12-04 HCV cirrhosis TAC, MMF, ST 22-05-12   7 TAC, MMF
18 F 20-09-99 HCV cirrhosis CYA, ST 18-06-12 13 CYA
4 E F 09-03-09 Alcoholic cirrhosis CYA, ST 21-03-12   3 CYA, MMF
G M 16-11-08 HCV cirrhosis TAC, DACLIZUMAB 30-04-12   3 CYA
J F 22-05-10 Hepatocarcinoma CYA, ST 02-05-12   2 CYA
L M 28-07-11 Primary biliary cirrhosis TAC, MMF, ST 19-06-12   1 TAC
Table 1  Patient characteristics
HBV: Hepatitis C virus; HCV: Hepatitis C virus.
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CD4+CD8low cells, all of them with diverse cytokine 
expression patterns whose role is not easy to interpret, 
although DP cells are known to appear in situations of 
long-term exposure to antigens. 
Antigenic areas of the GSTT1 protein
When we analyzed the relative contribution of each 
pool to the activation of T lymphocytes in each patient, 
we found that pools 3 and 4 seemed especially anti-
genic for the DP cells, whereas pool 4 did not stimulate 
any of the single CD4+ or CD8+ T cells of any patient in 
which other pools seem to have a more relevant role 
(Figure 2). A representative plot of flow cytometry data 
with cells gated on CD4+ first and then CD8, selecting 
those cells with a low expression of CD8, is shown in 
Figure 3. We have selected 3 patients with different 
degrees of activation after stimulation with the pools of 
peptides; the negative control (without peptide) is also 
shown and was subtracted to obtain the final values 
(Figure 3). 
Indirect presentation pathway
These results have to be interpreted in the context of an 
indirect allo-recognition pathway since the experiments 
were performed only in the presence of recipient cells. 
The recipients’ HLA genotypes are described in Table 
4, highlighting in bold HLA class Ⅰ and Ⅱ alleles with 
the best percentile ranks for presentation of GSTT1 
peptides, as concluded from the in silico analysis. We 
found a good correlation with part of the experimental 
results of T cell activation measured in terms of IL-4 
and/or IFNγ production by CD8+, CD4+ and CD4+CD8low 
T cells upon exposure to GSTT1 peptides. However, 
the fact that HLA genotyping was performed by 
low resolution methods constitutes a limitation of 
the analysis. When we placed the in silico-proposed 








































Table 2  Glutathione S-transferase T1 peptides and amino 
acid position and sequence




Figure 1  Polyclonal response of T cells upon recall with peptides of 
the glutathione S-transferase T1 protein. Percentages of activation upon 
exposure to the different pools are represented. Three cell types showed 
activation at different levels. A: Only CD8+ lymphocytes of patients included in 
group 1 showed activation. The numbers in the figure represent the highest 
value obtained for each pathway when activation was induced by different 
pools of peptides; B: Activation of CD4+ lymphocytes was observed in patients 
of groups 1 and 3; C: CD4+CD8low cells showed the highest percentage of 
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peptides along the GSTT1 amino acid sequence, we 
were able to define very clearly a highly antigenic 
zone of the protein that basically shared amino acids 
from positions 60 to 80 (Table 5). Interestingly, the 
selected peptides are long, not only for HLA class Ⅱ, as 
expected, but also for HLA class Ⅰ alleles.
DISCUSSION
In this study, we have demonstrated the existence 
of memory T cells specific for the GSTT1 antigen in 
patients with PC-rich rejection after GSTT1-mismatched 
liver transplants. The results support our initial hypo-
thesis in which both specific B and T cells are required 
to function simultaneously in the development of the 
immune response leading to PC-rich rejection. In 
fact, only patients diagnosed with the disease showed 
a combined T and B cell response, whereas those 
patients with specific T cells but lacking the humoral 
response never experienced this type of rejection.
The fact that GSTT1 is a drug metabolizing enzyme 
found in the cytoplasm of hepatocytes and cholan-
giocytes makes it difficult to explain a pathogenic 
role of anti-GSTT1 antibodies. Although it cannot be 
assumed that cytosolic antigens are never expressed 
on the cell surface[12], the presence of antibodies in all 
of the patients with a diagnosis of PC-rich rejection is 
evidence of specific B cells capable of presentation of 
GSTT1 to specific T cells. B cells are known to be critical 
for alloreactive T cells to differentiate into memory T 
cells[13,14]. In fact, a very interesting report by Zeng 
et al[15] demonstrated in an animal model of chronic 
allograft vasculopathy (CAV) that mice deficient in both 
B cells and antibodies were protected from CAV, while 
mice that were deficient for antibodies but not for B 
cells developed CAV. The conclusion was that B cells 
contributed to CAV by enhancing T-cell responses[15]. 
Very recently, Shiu et al[16] demonstrated that B cells 
are involved in supporting T-cell responses in patients 
with antibody-mediated rejection in a B-cell-dependent 
indirect T-cell alloreactivity.
CD4+ cells seem to have a predominant role in the 
 Group Pat # CD8+ CD4+ CD4+CD8low
IL-4 IFNγ IL-4/IFNγ IL-4 IFNγ IL-4/IFNγ IL-4 IFNγ IL-4/IFNγ
1   1 - - - 1.24% 1.41% - Δ Δ Δ
  2 1.7% - - 2.04% - -   8.23% -   3.44%
  3   4.92% - 3.54% 4.93% -   31.34% 10.77%   2.25% 78.95%
  4 - - - - - - - -   9.54%
  5 - - - - - - - -   4.56%
  6   2.36% 2.03% 1.15% 3.71% 2.45% 2.14% Δ Δ Δ
  7 - - - 3.19% 2.35% 5.63% Δ Δ Δ
2   8 - - - - - - Δ Δ Δ
  9 - - - - - - Δ Δ Δ
3 10 - - - - - - - -   6.63%
11 - - - - - - - - -
12 - - - - - - - - -
13 - - - - - - Δ Δ Δ
14 - - - 2.65% - 4.71% Δ Δ Δ
15 - - - 1.45% - 5.18% Δ Δ Δ
16 - - - - - - Δ Δ Δ
17 - - - - - -   1.68% 4.6% 29.58%
18 - - - - - -   2.51%   4.13% 43.05%
Control E - - - - - - Δ Δ Δ
G - - - - - - Δ Δ Δ
J - - - - - - Δ Δ Δ
L - - - - - - Δ Δ Δ
1Pathways of activation are defined by the production of IL-4, IFNγ or both cytokines simultaneously. “-“: No activation; “Δ”: Analysis was not possible due 
to the low number of gated cells. Group 1: don+/rec-, with Abs, with PC-rich rejection; Group 2: don+/rec-, with Abs, without PC-rich rejection; Group 3: 
don+/rec-, without Abs, without PC-rich rejection; Control group: don+/rec+.
Table 3  Specific immune response after stimulation of T lymphocytes in culture with glutathione S-transferase T1 peptides1
Pat # HLA-A* HLA-B* DRB1*
1 01 03 07 57 11 15
2 01 66 08 41 03 13
3 11 29 07 35 07 13
4 02 11 51 60 04 13
5 30 - 13 18 03 07
6 02 11 35 44 07 08
7 26 29 38 44 01 03
8 23 24 14 52 01 11
9 11 68 35 44 01 14
10 02 33 14 35 01 07
11 01 29 57 61 01 04
12 01 33 44 64 01 07
13 01 - 08 18 04 07
14 29 - 44 - 07 -
15 01 30 08 51 03 07
16 02 29 39 44 07 11
17 03 32 37 44 03 12
18 03 11 14 49 07 -
Table 4  Class Ⅰ and class Ⅱ human leukocyte antigen 
genotypes of the patients
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context of GSTT1 mismatch in the patients described 
in this study. Mouse models have provided evidence 
of the role of CD4+ T cells acting as effectors that 
directly mediate injury in renal allografts, while CD8+ 
T cells had very little influence in promoting graft 
dysfunction[17]. Similarly, CD4+ cells were sufficient to 
mediate rapid rejection of a cardiac allograft through 
the indirect pathway of alloantigen recognition[18]. 
Hence, CD4+ specific T cells are key elements for the 
progression of allograft immunity, especially within 
the CD4+ T cell indirect response. In the liver of mice 
with clinical manifestations of hepatitis, MHC class 
Ⅱ-expressing hepatocytes are able to act as APCs and 
activate specific CD4+ T lymphocytes[19].
The pathogenic role of GSTT1-specific CD8+ T 
cells in PC-rich rejection has not been explored. The 
results obtained in this study reveal the existence 
of reactive CD8+ cells in the group of patients with 
PC-rich rejection, with percentages of activation 
that range from 1.1% to 8.46%, which is not as 
low as expected in immunosuppressed patients. A 
substantial difference between the percentages of 
IFNγ-producing CD8+ T cells at diagnosis and during 
treatment with prednisolone has been demonstrated 
in patients with type 2 autoimmune hepatitis[20]. We 
should keep in mind that the patients with PC-rich 
rejection described in this study are under successful 
treatment with prednisone that has to be maintained 
throughout life. It would be very interesting to know 
the level of stimulation of cells obtained at diagnosis, 
before initiation of the treatment, since cells from 
immunosuppressed patients exhibit much lower levels 
of activation than immunocompetent cells. For that 
reason, it is even more remarkable that certain types of 
T lymphocytes from the patients with PC-rich rejection 
showed high percentages of activation.
The results of this study leave many questions 
about the function of GSTT1-specific CD4+CD8low T 
cells in the context of transplantation. Subgroups of 
CD4hiCD8low T cells have been described in chronic 
viral infections, with antigen specificity and memory 
phenotype[21,22], or in parasitic infections where the 
frequency of CD4+CD8low T cells was higher in Chagasic 
patients than in healthy donors[23]. In a study performed 
with human cells from CMV-seropositive patients, the 
CD4+CD8low population contained a two- to eight-fold 
higher frequency of antigen-specific IFNγ+ cells than 





A*01:01 FTLTESVAILLY1 62-73 12 0.1
A*02:01 YIFAKKNDIPFEL 18-30 13 0.1
CLRALWHKVMFPV 110-122 13 0.1
IKQKLMPWVLAMI 227-239 13 0.1
A*03:01 SVAILLYLTRKYK1 67-79 13 0.2
A*11:01 ESVAILLYLTRK1 66-77 12 0.1
A*29:02 FLTESVAILLY1 62-73 12 0.2
B*07:02 SPQTLAATLAEL 129-140 12 0.1
RPKLATWRQRVEAA 188-201 14 0.2
B*08:01 FAQVNPLKKVPAL 45-57 13 0.2
LAWQHTTLRRSCL   99-111 13 0.2
DPTIKQKLMPWVL 224-236 13 0.2
B*35:01 YPQDLQARARVDEY 85-98 14 0.1
B*44:02 TESVAILLY1 65-73   9   0.15
AELDVTLQL 138-146   9   0.15
Class Ⅱ
DRB1*01:03 GDFTLTESVAILLYL1 60-74 15 0.6
DRB1*07:01 ALKDGDFTLTESVAI1 56-70 15 0.4
DRB1*11:01 AILLYLTRKYKVPDY1 69-83 15 0.5
DRB1*12:01 SVAILLYLTRKYKVP1 67-81 15   0.72
DRB1*13:01 LTESVAILLYLTRKY1 64-78 15   0.17
DRB1*14:01 SVAILLYLTRKYKVP1 67-81 15   0.48
DRB1*15:01 ESVAILLYLTRKYKV1 66-80 15   0.41
Table 5  Identification of several regions of the glutathione 
S-transferase T1 protein, whose peptides would be suitable 
to be presented by human leukocyte antigen class Ⅰ and Ⅱ 
alleles of the patients based on in silico predictions
1Highly antigenic areas of the GSTT1 protein whose peptides are shared 






























































































Figure 2  Different areas of the glutathione S-transferase T1 protein 
induce different degrees of activation in patients’ cells. A: The majority of 
CD4+ T cells that showed some degree of activation recognized peptides in 
pools 5 (blue) and 3 (green) but never in pool 4 (purple); B: CD4+CD8low cells 
became stimulated almost homogeneously with in pools 3 (green) and 4 (purple); 
C: CD8+ lymphocytes that showed activation recognized peptides in different 
pools but never in pool 4 (purple). 
Martínez-Bravo MJ et al . Immune response against liver GSTT1 antigen
1122 September 28, 2017|Volume 9|Issue 27|WJH|www.wjgnet.com
the CD4+CD8- population[24]. It seems that this type 
of cell appears in chronic processes, mainly in viral 
infections, but this scenario could also be extended to 
the transplant setting where sustained expression of a 
foreign antigen, such as GSTT1, might lead to chronic 
rejection.
The terminologies used to describe post-transplant 
clinical situations with overlapping manifestations might 
be confusing. Late rejection, de novo autoimmune/
alloimmune hepatitis or idiopathic post-transplant 
hepatitis may all be part of immune-mediated injury[25]. 
The underlying pathology of the formerly called de 
novo autoimmune hepatitis was poorly understood, and 
diagnoses were based mainly on histological findings 
such as the presence of plasma cell rich infiltrates 
or hepatocyte rosette formation; however, because 
rosettes are poorly reproducible, some groups do not 
consider them a diagnostic feature[26]. 
Although we did not have enough samples to 
check for memory markers, based on the short time 
of stimulation in vitro (48 h), we can say that GSTT1-
specific lymphocytes are memory cells. It is still too 
soon to propose a model, as we have not yet tested 
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Figure 3  Representative plots showing CD4+CD8low T lymphocyte activation in terms of cytokine production. Production of IL-4 and/or IFNγ was analyzed 
after exposure of the cells to the glutathione S-transferase T1 peptides. As an example, patient 3 had 78.85% of the double positive cells activated with pool 3 and 2.9% 
with pool 6. Patient 4 had 6.05% of cells activated with pool 3, whereas pool 5 did not have any effect. Patient 17 showed 21.21% of cell activation with pool 3, but no 
response was observed when the cells were cultured with pool 2. In all the cases, the cells produced both cytokines, indicating a Th0 type of response.
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confronted with GSTT1 peptides presented via the 
direct pathway. Apparently, there is not a predominant 
HLA class Ⅰ or Ⅱ allele among the donors of the 
patients with PC-rich rejection that could explain why 
some patients develop rejection and others do not. 
Given that donor cells are not available, in future 
studies we will have to design strategies to demonstrate 
the existence of donor HLA-restricted GSTT1-specific 
T lymphocytes through the use of artificial molecules 
such as pentamers, as well as cytotoxicity assays on 
“donor-like” target cells. 
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